|
May 15
|
Elevation Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates
|
|
May 14
|
Allogene's Q1 Earnings In Line With Estimates, Sales Nil
|
|
Apr 18
|
GSK prepares to relaunch Blenrep; Activists challenge another ‘zombie’ biotech
|
|
Oct 9
|
Empery Asset Management's Strategic Acquisition in Elevation Oncology
|
|
Jun 27
|
Elevation Oncology Announces Planned Combination Strategy for EO-3021 in Patients with Gastric or Gastroesophageal Junction Cancer
|
|
May 7
|
Elevation Oncology to Present at the Citizens JMP Life Sciences Conference
|
|
May 2
|
Elevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Achievements
|
|
Apr 8
|
Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024
|
|
Jan 13
|
With 29% ownership in Elevation Oncology, Inc. (NASDAQ:ELEV), hedge funds investors have a lot riding on the business
|
|
Sep 5
|
Elevation Oncology to Present at the H.C. Wainwright 25th Annual Global Investment Conference
|
|
May 19
|
Private equity firms among Elevation Oncology, Inc.'s (NASDAQ:ELEV) largest shareholders, saw gain in holdings value after stock jumped 34% last week
|